Filtered By:
Nutrition: Vitamin B9

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 52 results found since Jan 2013.

Targeted Combination of Antioxidative and Anti ‐Inflammatory Therapy of Rheumatoid Arthritis using Multifunctional Dendrimer‐Entrapped Gold Nanoparticles as a Platform
A multifunctional dendrimer nanoplatform is developed to have entrapped gold nanoparticles within dendrimer interiors, and covalently linked PEGylated alpha ‐tocopheryl succinate, PEGylated folic acid, and 1,3‐propane sultone on dendrimer peripheries. The designed nanoplatform enables co‐delivery of drug/gene to macrophage cells, effectively scavenging reactive oxygen species and inhibiting tumor necrosis factor‐α expression for combined antiox idative and anti‐inflammatory therapy of rheumatoid arthritis. AbstractAbundant reactive oxygen species and tumor necrosis factor ‐α (TNF‐α) cytokine supply of M1...
Source: Small - November 17, 2020 Category: Nanotechnology Authors: Jin Li, Liang Chen, Xiaoying Xu, Yu Fan, Xue Xue, Mingwu Shen, Xiangyang Shi Tags: Full Paper Source Type: research

Targeting CD146 using folic acid-conjugated nanoparticles and suppression of tumor growth in a mouse glioma model.
CONCLUSIONS: CD146 is a potential therapeutic target, and folic acid-conjugated NPs delivering siRNA may facilitate gene therapy in malignant gliomas. PMID: 32707539 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - July 23, 2020 Category: Neurosurgery Authors: Fukui N, Yawata T, Nakajo T, Kawanishi Y, Higashi Y, Yamashita T, Aratake T, Honke K, Ueba T Tags: J Neurosurg Source Type: research

Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPAR α.
CONCLUSION: Folic acid improves hepatic lipid metabolism by upregulating PPARα levels via a SIRT1-dependent mechanism and restores hepatic one-carbon metabolism and diversity of gut microbiota, thereby attenuating HFD-induced NASH in rats. PMID: 32476787 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - May 13, 2020 Category: Gastroenterology Authors: Xin FZ, Zhao ZH, Zhang RN, Pan Q, Gong ZZ, Sun C, Fan JG Tags: World J Gastroenterol Source Type: research

Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice.
Abstract Toxoplasma gondii (T. gondii), an obligatory intracellular parasite, is the etiologic agent of toxoplasmosis. Dihydrofolate reductase-thymidylate synthase (DHFR-TS) is one of the most important enzymes in toxoplasma folic acid cycle. Due to the emergence of resistance in RH strain of T. gondii against pyrimethamine that acts via DHFR-TS inhibition and also the crucial role of small interference RNA (siRNA) technology in gene silencing, we aimed to use siRNA to knock down DHFR-TS gene expression in T. gondii as a therapeutic target against toxoplasmosis in a mouse model. Based on the DHFR-TS gene sequence,...
Source: Acta Tropica - April 7, 2020 Category: Infectious Diseases Authors: Azimi-Resketi M, Eskandarian A, Ganjalikhani-Hakemi M, Zohrabi T Tags: Acta Trop Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)
Publication date: May 2020Source: Biomedicine & Pharmacotherapy, Volume 125Author(s): Yinxue Song, Bin Zhou, Xiangyang Du, Yong Wang, Jie Zhang, Yanqiu Ai, Zongjiang Xia, Gaofeng Zhao
Source: Biomedicine and Pharmacotherapy - February 25, 2020 Category: Drugs & Pharmacology Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Abstract Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collect...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 21, 2020 Category: Drugs & Pharmacology Authors: Song Y, Zhou B, Du X, Wang Y, Zhang J, Ai Y, Xia Z, Zhao G Tags: Biomed Pharmacother Source Type: research

Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells
Publication date: Available online 18 February 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Jing Chen, Yushun Dou, Yue Tang, Xinru ZhangAbstractWe developed a STAT3 silencing siRNA to both tumor cells and M2 macrophages. The dual-targeting system prepared by electronic self-assembly was composed of folic acid-conjugated carboxymethyl chitosan for targeting and cationic chitosan derivatives for siRNA package. The effects of siRNA delivery was investigated in M2 macropahges and Lewis lung cancer cells(LLC). Due to the enhanced delivery efficiency, the dual-targeting delivery system exhibited a hig...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - February 19, 2020 Category: Nanotechnology Source Type: research

Cholic acid-based mixed micelles as siRNA delivery agents for gene therapy
In this study, we demonstrate the use of lipids as co-surfactants for the preparation of mixed micelles to improve the siRNA delivery of cholic acid-based block copolymers. Poly(allyl glycidyl ether) (PAGE) and poly(ethylene glycol) (PEG) were polymerized on the surface of cholic acid to afford a star-shaped block copolymer with four arms (CA-PAGE-b-PEG)4. The allyl groups of PAGE were functionalized to bear primary or tertiary amines and folic acid was grafted onto the PEG chain end to increase cell uptake. (CA-PAGE-b-PEG)4 functionalized with either primary or tertiary amines show high siRNA complexation with close to 10...
Source: International Journal of Pharmaceutics - January 26, 2020 Category: Drugs & Pharmacology Source Type: research

New approaches to tumour therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles.
Conclusions: The formulation we developed is a potential carrier system for both treatment of cancer and prevention of pain, especially for metastatic cancers. PMID: 31491363 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - September 8, 2019 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research

Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors.
We report the use of small interfering RNAs (siRNAs) against ARHGEF4, CCDC88A, LAMTOR2, mTOR, NUP85, and WASF2 and folic acid (FA)-modified polyethylene glycol (PEG)-chitosan oligosaccharide lactate (COL) nanoparticles for targeting, imaging, delivery, gene silencing, and inhibition of invasiveness and metastasis in an orthotopic xenograft model. In vitro assays revealed that these siRNA-FA-PEG-COL nanoparticles were specifically inserted into pancreatic cancer cells compared to immortalized normal pancreatic epithelial cells and knocked down expression of the corresponding targets in pancreatic cancer cells. Cell motility...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Current Development of siRNA Bioconjugates: From Research to the Clinic
In this study, it was shown that the main factor determining the nature of the biodistribution of conjugates is their lipophilicity. Conjugates of siRNA with lower lipophilicity; i.e., derivatives of retinoic acid, lithocholic acid, and docosahexanoic acid with greater efficiency than cholesterol conjugates accumulated in the kidneys, bladder, and lungs of the mouse after subcutaneous injection (Biscans et al., 2018). This fact is consistent with previous data that showed that more lipophilic conjugates bind more efficiently to serum components, and thus are not excreted by the kidneys (Wolfrum et al., 2007; Osborn et al.,...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research

NF κB and Kidney Injury
Conclusion As a critical regulator of inflammation and cell survival, the NFκB pathway is a promising target for diagnosing and treating kidney diseases. For modulation of the NFκB pathway in the clinic, a number of molecules can effectively inhibit NFκB signaling by targeting the receptors, associated adaptors, IKKs, IκBs and transcriptional regulators (144). There is further clinical evidence on small-molecule inhibitors of IKKα and NIK from recent trials on anti-cancer therapies (145). These clinical trials showed that the cancer-selective pharmacodynamic response of DTP3, the co...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl- β-Cyclodextrin Conjugate
AbstractWe have previously reported the utility of folate-polyethylene glycol-appended dendrimer conjugate with glucuronylglucosyl- β-cyclodextrin (Fol-PEG-GUG-β-CDE) (generation 3) as a tumor-selective carrier for siRNA against polo-like kinase 1 (siPLK1)in vitro. In the present study, we evaluated the potential of Fol-PEG-GUG- β-CDE as a carrier for the low-molecular antitumor drug doxorubicin (DOX). Further, to fabricate advanced antitumor agents, we have prepared a ternary complex of Fol-PEG-GUG-β-CDE/DOX/siPLK1 and evaluated its antitumor activity bothin vitro andin vivo. Fol-PEG-GUG- β-CDE released DOX in an aci...
Source: The AAPS Journal - April 15, 2019 Category: Drugs & Pharmacology Source Type: research